This page shows you your search results in order of relevance. This is page number 2.

Order by Relevance | Date

Total 442 results found since Jan 2013.

Z-Medica Bolsters Hemostatic Product Line with Acquisition of Novacol®
WALLINGFORD, CONN. — Z-Medica, a leading developer and marketer of hemostatic agents, today announced that they have signed a definitive agreement with TAUREON, headquartered in The Netherlands, to acquire Novacol®, a Class III resorbable hemostatic product.Novacol is currently sold in Europe and South Korea. Z-Medica will continue to support that marketing strategy while making plans to expand the product offering into other countries.“Given our QuikClot portfolio of hemostatic dressings, it was a natural fit for us to augment both our product line and our international presence with Novacol,” said Z-Medica’s Pre...
Source: Medical Hemostat - May 5, 2014 Category: Technology Consultants Authors: hemostatguy at gmail.com (hemostat guy) Source Type: blogs

The Medicines Company Adds Novel, Approved, Surgical Sealant to Its Surgical Hemostasis Portfolio Acquires Tenaxis Medical, Inc.
PARSIPPANY, NJ and MOUNTAIN VIEW, CA -- (Marketwired) -- 04/23/14 -- The Medicines Company (NASDAQ: MDCO) and Tenaxis Medical, Inc. (Tenaxis) today announced an agreement for The Medicines Company to acquire Tenaxis. Tenaxis's sole product, which mechanically seals both human tissue and artificial grafts is approved, but not launched in the US -- having received US PMA approval from the FDA in March 2013 as a vascular sealant. The product is also approved with a European CE Mark as a surgical sealant applicable to cardiovascular, general, urological, and thoracic surgery. The addition of the Tenaxis product adds another so...
Source: Medical Hemostat - April 23, 2014 Category: Technology Consultants Authors: hemostatguy at gmail.com (hemostat guy) Source Type: blogs

FDA Accepts Biologic License Application for Fibrocaps Hemostatic Agent
The Medicines Company has announced that the U.S. Food and Drug Administration (FDA) has accepted the filing of a biologic license application (BLA) for the investigational hemostatic agent Fibrocaps, a dry powder formulation of fibrinogen and thrombin being developed to aid in hemostasis during surgery, where control of mild or moderate bleeding by conventional means is ineffective or impractical. The FDA action date (PDUFA date) for Fibrocaps is January 31, 2015. In August 2013, The Medicines Company announced that the Phase III trial, FINISH-3, which studied a total of 719 patients across 54 sites in the U.S. and W...
Source: Medical Hemostat - April 5, 2014 Category: Technology Consultants Authors: hemostatguy at gmail.com (hemostat guy) Source Type: blogs

HaemoCer approved for use in China and Canada
BioCer Entwicklungs GmbH (BCE), a German implantable biological medical device development and manufacturing company, announced today that it has achieved approval to commence sales of HaemoCer™, an Absorbable Polysaccharide Hemostat (APH), in the People's Republic of China."BioCer has now achieved near comprehensive Asia-Pacific regional representation, and the addition of the PRC approval of HaemoCer™ is a significant milestone," Dr Markus Heinlein, Managing Director stated. "The entry into China of our first product HaemoCer™ has been assisted by the early establishment of region...
Source: Medical Hemostat - October 8, 2014 Category: Technology Consultants Authors: hemostatguy at gmail.com (hemostat guy) Source Type: blogs

Z-Medica Bolsters Hemostatic Product Line with Acquisition of Novacol ®
WALLINGFORD, CONN. — Z-Medica, a leading developer and marketer of hemostatic agents, today announced that they have signed a definitive agreement with TAUREON, headquartered in The Netherlands, to acquire Novacol®, a Class III resorbable hemostatic product. Novacol is currently sold in Europe and South Korea. Z-Medica will continue to support that marketing strategy while making plans to expand the product offering into other countries. “Given our QuikClot portfolio of hemostatic dressings, it was a natural fit for us to augment both our product line and our international presence with Novacol,” said Z-Medica...
Source: Medical Hemostat - May 4, 2014 Category: Medical Equipment Authors: hemostatguy at gmail.com (hemostat guy) Source Type: blogs

The effects of Ankaferd hemostat on preventing oral mucositis in colorectal cancer patients receiving chemotherapy
ConclusionsIt was determined that Ankaferd hemostat is effective in preventing oral mucositis due to chemotherapy in adult patients diagnosed with colorectal cancer. In addition, it has been suggested to conduct new studies on the effectiveness of Ankaferd hemostat in the prevention of mucositis in different groups.Trial registrationThe study was registered at ClinicalTrials.gov (ID: NCT05438771, Date: 25.06.2022).
Source: Supportive Care in Cancer - June 8, 2023 Category: Cancer & Oncology Source Type: research

Use of a plant-based polysaccharide hemostat for the treatment of sternal bleeding after median sternotomy
Conclusion: Polysaccharide hemostats appear to be safe and effective for bleeding control of the sternum.
Source: Journal of Cardiothoracic Surgery - April 24, 2015 Category: Cardiovascular & Thoracic Surgery Authors: Christoph SchmitzRalf Sodian Source Type: research

Evaluation of the effects of Ankaferd hemostat application on bone regeneration in rats with calvarial defects: histochemical, immunohistochemical and scintigraphic study
CONCLUSIONS: In our study, it has been concluded that the ABS yields affirmative effects on the bone healing, while bone wax leads to negative impact on the bone regeneration. Scintigraphic, histochemical and immunohistochemical data support the affirmative impact of the ABS hemostat application upon the bone regeneration apart from the quick stop of hemorrhage.PMID:34355787 | DOI:10.5603/FM.a2021.0074
Source: Folia Morphologica - August 6, 2021 Category: Anatomy Authors: M Turgut S Karademir H K Ba şaoğlu C Tomruk E O Cetin Y Uyanikgil A Cengiz Source Type: research